Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Treatment Options Expanding for Benign Hematologic Disorders

April 30th 2019

Nathan T. Connell, MD, MPH, shares key updates in the rapidly evolving treatment paradigms of benign hematologic disorders.

Dr. Nadeem on Sequencing Considerations in Multiple Myeloma

April 29th 2019

Omar Nadeem, MD, a physician at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, discusses sequencing challenges in multiple myeloma.

Research Propels Forward With CAR T-Cell Therapy in Pediatric ALL

April 28th 2019

Christine N. Duncan, MD, discusses the current components of CAR T-cell therapy in pediatric acute lymphoblastic leukemia.

European Approval Sought for Luspatercept for Anemias

April 26th 2019

A marketing authorization application has been submitted to the European Medicines Agency for luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndrome–associated anemia with ring sideroblasts who require red blood cell transfusions and have not received or are ineligible to receive erythropoiesis-stimulating agents.

Frontline Lenalidomide/R-CHOP Combo Misses Primary Endpoint in DLBCL

April 26th 2019

The combination of lenalidomide (Revlimid) with rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; R2-CHOP) did not improve progression-free survival compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell-type diffuse large B-cell lymphoma, missing the primary endpoint of the phase III ROBUST trial.

Dr. Mullighan on Germline Predisposition to ALL

April 26th 2019

Charles G. Mullighan, MBBS, MSc, MD, member, St. Jude Faculty, deputy director, Comprehensive Cancer Center, co-leader, Hematological Malignancies Program, medical director, St. Jude Biorepository, William E. Evans Endowed Chair, St. Jude Children’s Research Hospital, discusses germline predisposition to acute lymphoblastic leukemia (ALL).

Tagraxofusp Elicits Responses in Treatment-Naive and Relapsed BPDCN

April 25th 2019

Tagraxofusp led to a 90% overall response rate as a first-line therapy in patients with blastic plasmacytoid dendritic cell neoplasm.

Dr. Shah on TKI Treatment Discontinuation in CML

April 24th 2019

Neil P. Shah, MD, PhD, professor of medicine, Division of Hematology and Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses TKI treatment discontinuation in patients with chronic myeloid leukemia.

Metastatic Cancer Is a Chronic Condition

April 23rd 2019

Advancements in targeted therapy and immunotherapy have led to a rapidly increasing number of patients with metastatic cancer becoming patients with chronic cancer.

Sequencing Challenges Emerge in Myeloma as Options Expand

April 22nd 2019

Omar Nadeem, MD, highlights exciting approaches that have emerged in relapsed/refractory myeloma, such as CAR T-cell therapy, and shares unanswered questions that future research should address.

Monoclonal Antibodies Shake Up Myeloma Paradigm

April 22nd 2019

Paul G. Richardson, MD, highlights the many promising agents that have emerged in relapsed/refractory multiple myeloma in recent years, remaining challenges, and hope for continued progress.

FDA Schedules ODAC Meetings for Pexidartinib in TGCT and Quizartinib in AML

April 19th 2019

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for May 14, 2019, to discuss a new drug application for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor.

Daratumumab Elicits Low Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

April 17th 2019

Daratumumab was associated with low overall response rates in patients with relapsed/refractory diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, missing the primary endpoint of a phase II trial published in Clinical Lymphoma, Myeloma & Leukemia.1

Ivosidenib Holds Greatest Benefit for Older Patients With IDH1-Mutant AML

April 16th 2019

Courtney D. DiNardo, MD, MSCE, discusses the findings of the phase I dose-escalating study that led to the initial approval of ivosidenib for adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.

Quizartinib Poised to Expand FLT3 Inhibition Options in AML

April 16th 2019

Quizartinib, a novel small molecule FLT3 inhibitor, is moving through the pipeline of new drugs under development for patients with FLT3-mutated acute myeloid leukemia, part of a menu of targeted treatment options that is expanding as investigators learn more about the molecular heterogeneity of the disease.

Direct Oral Anticoagulants Signal Change in VTE Prevention

April 16th 2019

Investigators at Cleveland Clinic have demonstrated that the direct oral anticoagulant rivaroxaban significantly reduces venous thromboembolism (VTE) and VTE-related death for patients with high-risk cancers treated in the outpatient setting.

Dr. Moskowitz on PET-Adapted Therapy in Advanced Hodgkin Lymphoma

April 12th 2019

Craig Moskowitz, MD, physician-in-chief, Oncology Service Line, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of PET-adapted therapy in the treatment of patients with advanced-stage Hodgkin lymphoma.

Oral Anticoagulants Demonstrate Value in Management of Acute VTE

April 11th 2019

The optimal anticoagulant takes into consideration a variety of components, including patient preference, the indication for anticoagulation, comorbidities, reversibility, and other factors relevant to the clinical scenario.

Lenalidomide/Rituximab Data Published as FDA Weighs Non-Hodgkin Lymphoma Approval

April 9th 2019

The R2 regimen of lenalidomide plus rituximab significantly reduced the risk of disease progression or death compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma, according to results from the pivotal phase III AUGMENT trial.

FDA Approval Sought for Luspatercept for Anemias

April 5th 2019

A supplemental biologics license application has been submitted to the FDA for luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndrome–associated anemia with ring sideroblasts who require red blood cell transfusions, and also for adult patients with beta-thalassemia–associated anemia who require such transfusions.